Cargando…

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase

Bempedoic acid (ETC-1002), a novel therapeutic approach for low-density lipoprotein cholesterol (LDL-C) lowering, inhibits ATP citrate lyase (ACL), an enzyme involved in fatty acid and cholesterol synthesis. Although rodent studies suggested potential effects of ACL inhibition on both fatty acid and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilen, Ozlem, Ballantyne, Christie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Nonstatin Drugs (E. deGoma, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035316/ https://www.ncbi.nlm.nih.gov/pubmed/27663902 http://dx.doi.org/10.1007/s11883-016-0611-4

Ejemplares similares

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges
por: Elbers, L.P.B., et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?
por: Toledo-Ibelles, Paola, et al.
Publicado: (2018)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
por: Pinkosky, Stephen L., et al.
Publicado: (2016)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Allosteric role of the citrate synthase homology domain of ATP citrate lyase
por: Wei, Xuepeng, et al.
Publicado: (2023)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Exploring the Role of ATP-Citrate Lyase in the Immune System
por: Dominguez, Monica, et al.
Publicado: (2021)

Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques
por: Baardman, Jeroen, et al.
Publicado: (2020)

ATP-citrate lyase promotes axonal transport across species
por: Even, Aviel, et al.
Publicado: (2021)

Cytoskeletal association of ATP citrate lyase controls the mechanodynamics of macropinocytosis
por: Puccini, Joseph, et al.
Publicado: (2023)

Correction to: Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

ATP citrate lyase knockdown impacts cancer stem cells in vitro
por: Hanai, J-i, et al.
Publicado: (2013)

ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score
por: Sanjay, K.V., et al.
Publicado: (2021)

Polarization of Human Macrophages by Interleukin-4 Does Not Require ATP-Citrate Lyase
por: Namgaladze, Dmitry, et al.
Publicado: (2018)

Publisher Correction: ATP-citrate lyase promotes axonal transport across species
por: Even, Aviel, et al.
Publicado: (2021)

Discovery of Flavonoids as Novel Inhibitors of ATP Citrate Lyase: Structure–Activity Relationship and Inhibition Profiles
por: Wang, Pan, et al.
Publicado: (2022)

Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease
por: Gunn, Laura H., et al.
Publicado: (2022)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
por: Ballantyne, Christie M., et al.
Publicado: (2022)

Correlation of ATP Citrate Lyase and Acetyl CoA Levels with Trichothecene Production in Fusarium graminearum
por: Sakamoto, Naoko, et al.
Publicado: (2013)

Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer
por: WANG, YU, et al.
Publicado: (2012)

Caspase-10 inhibits ATP-citrate lyase-mediated metabolic and epigenetic reprogramming to suppress tumorigenesis
por: Kumari, Rajni, et al.
Publicado: (2019)

ATP-citrate lyase B (ACLB) negatively affects cell death and resistance to Verticillium wilt
por: Liu, Fujie, et al.
Publicado: (2022)

ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db/db mouse model
por: Zhan, Zishun, et al.
Publicado: (2022)

Guggulsterone inhibits prostate cancer growth via inactivation of Akt regulated by ATP citrate lyase signaling
por: Gao, Yajuan, et al.
Publicado: (2015)

Functional polymorphisms of ATP citrate lyase gene predicts clinical outcome of patients with advanced colorectal cancer
por: Xie, Shuang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6fgeflul4qgm2951iui6gs7kbd